SHORT TITLE; FINDING.

SEC. 401. SHORT TITLE; FINDING. (a) [21 U.S.C. 301 note] Short Title.—This title may be cited as the “Biosimilar User Fee Amendments of 2017”. (b) [21 U.S.C. 379j-51 note] Finding.—The Congress finds that the fees authorized by the amendments made in this title will be dedicated to expediting the process for the review of biosimilar biological product applications, including postmarket safety activities, as set forth in the goals identified for purposes of part 8 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record.